📣 VC round data is live. Check it out!
- Public Comps
- Ever Supreme Bio Technology
Ever Supreme Bio Technology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ever Supreme Bio Technology and similar public comparables like Upstream Bio, Abclon, Emergent BioSolutions, Neurogene and more.
Ever Supreme Bio Technology Overview
About Ever Supreme Bio Technology
Ever Supreme Bio Technology Co Ltd is a Taiwan-based company. The company is engaged in research, development, and manufacturing of new drugs related to human mesenchymal stem cells and immune cells. The company operates in two segments: Cell Preparation Business Unit and Other Operating Business. The company gained a majority of revenue from the cell preparation Business, which is engaged in the research, development, manufacture, and sales of various new drugs and cell preparations, and investments related to biotechnology and medical industry businesses.
Founded
2016
HQ

Employees
99
Website
Financials (LTM)
EV
$428M
Valuation Multiples
Start free trialEver Supreme Bio Technology Financials
Ever Supreme Bio Technology reported last 12-month revenue of $34M.
In the same LTM period, Ever Supreme Bio Technology generated $16M in net income.
Revenue (LTM)
Ever Supreme Bio Technology P&L
In the most recent fiscal year, Ever Supreme Bio Technology reported revenue of $33M and EBITDA of $17M.
Ever Supreme Bio Technology is profitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 54%, and net margin of 42%.
Financial data powered by Morningstar, Inc.
Ever Supreme Bio Technology Stock Performance
Ever Supreme Bio Technology has current market cap of $441M, and enterprise value of $428M.
Market Cap Evolution
Ever Supreme Bio Technology's stock price is $4.33.
Ever Supreme Bio Technology share price increased by 1.5% in the last 30 days, and decreased by 11.2% in the last year.
Ever Supreme Bio Technology has an EPS (earnings per share) of $0.14.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $428M | $441M | 1.5% | 1.5% | -1.6% | -11.2% | $0.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEver Supreme Bio Technology Valuation Multiples
Ever Supreme Bio Technology trades at 12.7x EV/Revenue multiple, and 24.5x EV/EBITDA.
EV / Revenue (LTM)
Ever Supreme Bio Technology Financial Valuation Multiples
As of June 2, 2026, Ever Supreme Bio Technology has market cap of $441M and EV of $428M.
Ever Supreme Bio Technology has a P/E ratio of 27.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ever Supreme Bio Technology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Ever Supreme Bio Technology Margins & Growth Rates
Ever Supreme Bio Technology grew revenue by 7% and net profit by 44% in the last fiscal year.
In the most recent fiscal year, Ever Supreme Bio Technology reported gross margin of 70%, EBITDA margin of 54%, and net margin of 42%.
Ever Supreme Bio Technology Margins
Ever Supreme Bio Technology Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Ever Supreme Bio Technology Operational KPIs
Ever Supreme Bio Technology's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Ever Supreme Bio Technology Competitors
Ever Supreme Bio Technology competitors include Upstream Bio, Abclon, Emergent BioSolutions, Neurogene, Sagimet Biosciences, Kamada, TYK Medicines, Shattuck Labs, ADC Therapeutics and Monopar Therapeutics.
Most Ever Supreme Bio Technology public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 51.2x | 57.4x | (0.9x) | - | |||
| 132.8x | - | (38.3x) | - | |||
| 1.1x | 1.2x | 3.6x | 4.4x | |||
| - | - | (2.3x) | - | |||
| - | - | (6.0x) | - | |||
| 2.1x | 2.0x | 9.1x | 8.3x | |||
| - | - | (10.4x) | - | |||
| 345.7x | 595.2x | (7.2x) | (6.4x) | |||
This data is available for Pro users. Sign up to see all Ever Supreme Bio Technology competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ever Supreme Bio Technology
| When was Ever Supreme Bio Technology founded? | Ever Supreme Bio Technology was founded in 2016. |
| Where is Ever Supreme Bio Technology headquartered? | Ever Supreme Bio Technology is headquartered in Taiwan. |
| How many employees does Ever Supreme Bio Technology have? | As of today, Ever Supreme Bio Technology has over 99 employees. |
| Is Ever Supreme Bio Technology publicly listed? | Yes, Ever Supreme Bio Technology is a public company listed on Taipei Exchange. |
| What is the stock symbol of Ever Supreme Bio Technology? | Ever Supreme Bio Technology trades under 6712 ticker. |
| When did Ever Supreme Bio Technology go public? | Ever Supreme Bio Technology went public in 2018. |
| Who are competitors of Ever Supreme Bio Technology? | Ever Supreme Bio Technology main competitors include Upstream Bio, Abclon, Emergent BioSolutions, Neurogene, Sagimet Biosciences, Kamada, TYK Medicines, Shattuck Labs, ADC Therapeutics, Monopar Therapeutics. |
| What is the current market cap of Ever Supreme Bio Technology? | Ever Supreme Bio Technology's current market cap is $441M. |
| What is the current revenue of Ever Supreme Bio Technology? | Ever Supreme Bio Technology's last 12 months revenue is $34M. |
| What is the current revenue growth of Ever Supreme Bio Technology? | Ever Supreme Bio Technology revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Ever Supreme Bio Technology? | Current revenue multiple of Ever Supreme Bio Technology is 12.7x. |
| What is the current net income of Ever Supreme Bio Technology? | Ever Supreme Bio Technology's last 12 months net income is $16M. |
| What is the current FCF of Ever Supreme Bio Technology? | Ever Supreme Bio Technology's last 12 months FCF is $3M. |
| What is Ever Supreme Bio Technology's FCF margin? | Ever Supreme Bio Technology's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Ever Supreme Bio Technology? | Current FCF multiple of Ever Supreme Bio Technology is 140.2x. |
| How many companies Ever Supreme Bio Technology has acquired to date? | Ever Supreme Bio Technology hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Ever Supreme Bio Technology has invested to date? | Ever Supreme Bio Technology hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Ever Supreme Bio Technology
Lists including Ever Supreme Bio Technology
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.